Search for a doctor

Tyler S. Oesterle, M.D., M.P.H.

Publications

  1. Karpyak VM, Coombes BJ, Geske JR, Pazdernik VM, Schneekloth T, Kolla BP, Oesterle T, Loukianova LL, Skime MK, Ho AM, Ngo Q, Skillon C, Ho MF, Weinshilboum R, Biernacka JM. Genetic predisposition to major depressive disorder differentially impacts alcohol consumption and high-risk drinking situations in men and women with alcohol use disorder. Drug Alcohol Depend. 2023 Feb 1; 243:109753 Epub 2022 Dec 24
    View PubMed
  2. Sharma P, Holland A, Sheikh T, Novy B, Oesterle T, Platt R, Hammond CJ. Primary care provider attitudes, experiences and practices about cannabidiol (CBD) and barriers to patient-provider communication about CBD use: A qualitative study. PEC Innov. 2022 Dec; 1:100044 Epub 2022 Apr 28
    View PubMed
  3. Oesterle TS, Karpyak VM, Coombes BJ, Athreya AP, Breitinger SA, Correa da Costa S, Dana Gerberi DJ. Systematic review: Wearable remote monitoring to detect nonalcohol/nonnicotine-related substance use disorder symptoms. Am J Addict. 2022 Nov; 31 (6):535-545 Epub 2022 Sept 05
    View PubMed
  4. Ho MF, Zhang C, Moon I, Zhu X, Coombes BJ, Biernacka J, Skime M, Oesterle TS, Karpyak VM, Schmidt K, Gliske K, Ngo Q, Skillon C, Seppala MD, Li H, Weinshilboum RM. Single cell transcriptomics reveals distinct transcriptional responses to oxycodone and buprenorphine by iPSC-derived brain organoids from patients with opioid use disorder. Mol Psychiatry. 2022 Oct 27 [Epub ahead of print]
    View PubMed
  5. Kamath CC, Kelpin SS, Patten CA, Rummans TA, Kremers HM, Oesterle TS, Williams MD, Breitinger SA. Shaping the Screening, Behavioral Intervention, and Referral to Treatment (SBIRT) Model for Treatment of Alcohol Use Disorder in the COVID-19 Era. Mayo Clin Proc. 2022 Oct; 97 (10):1774-1779 Epub 2022 July 19
    View PubMed
  6. da Costa SC, Oesterle T, Rummans TA, Richelson E, Gold M. Psychedelic drugs for psychiatric disorders. J Neurol Sci. 2022 Sep 15; 440:120332 Epub 2022 July 05
    View PubMed
  7. Ho MF, Zhang C, Moon I, Wei L, Coombes B, Biernacka J, Skime M, Choi DS, Frye M, Schmidt K, Gliske K, Braughton J, Ngo Q, Skillon C, Seppala M, Oesterle T, Karpyak V, Li H, Weinshilboum R. Genome-wide association study for circulating FGF21 in patients with alcohol use disorder: Molecular links between the SNHG16 locus and catecholamine metabolism. Mol Metab. 2022 Sep; 63:101534 Epub 2022 June 22
    View PubMed
  8. Kamath C, Kelpin S, Patten CA, Rummans TA, Maradit H, Oesterle TS, Williams MD, Breitinger S. Shaping the Screening, Behavioral Intervention and Referral to Treatment (SBIRT) Model for Treatment of Alcohol Use Disorder in the COVID 19 era ? (MAYOCLINPROC-D-21-00804R1 ) Mayo Clinic Proceedings. 2022.
  9. Ho MF, Zhang C, Wei L, Zhang L, Moon I, Geske JR, Skime MK, Choi DS, Biernacka JM, Oesterle TS, Frye MA, Seppala MD, Karpyak VM, Li H, Weinshilboum RM. Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study. Br J Pharmacol. 2022 Jul; 179 (13):3330-3345 Epub 2022 Feb 08
    View PubMed
  10. Romanowicz M, Oesterle TS, Croarkin PE, Sutor B. Measuring patient satisfaction in an outpatient psychiatric clinic. What factors play a role? Ann Gen Psychiatry. 2022 Jan 18; 21 (1):2
    View PubMed
  11. Ho MF, Zhang C, Moon I, Coombes BJ, Biernacka J, Skime M, Choi DS, Croarkin PE, Frye MA, Ngo Q, Skillon C, Oesterle TS, Karpyak VM, Li H, Weinshilboum RM. Plasma TNFSF10 levels associated with acamprosate treatment response in patients with alcohol use disorder. Front Pharmacol. 2022; 13:986238 Epub 2022 Sept 01
    View PubMed
  12. Carley JA, Oesterle T. Therapeutic Approaches to Opioid Use Disorder: What is the Current Standard of Care? Int J Gen Med. 2021; 14:2305-2311 Epub 2021 June 03
    View PubMed
  13. Oesterle TS, Kolla B, Risma CJ, Breitinger SA, Rakocevic DB, Loukianova LL, Hall-Flavin DK, Gentry MT, Rummans TA, Chauhan M, Gold MS. Substance Use Disorders and Telehealth in the COVID-19 Pandemic Era: A New Outlook. Mayo Clin Proc. 2020 Dec; 95 (12):2709-2718 Epub 2020 Oct 21
    View PubMed
  14. Kolla BP, Oesterle T, Gold M, Southwick F, Rummans T. Infectious diseases occurring in the context of substance use disorders: A concise review. J Neurol Sci. 2020 Apr 15; 411:116719 Epub 2020 Jan 31
    View PubMed
  15. Oesterle TS, Kolla BP, Rummans TA, Gold MS. Medication-assisted therapies for opioid use disorders in patients with chronic pain. J Neurol Sci. 2020 Apr 15; 411:116728 Epub 2020 Feb 11
    View PubMed
  16. Oesterle TS, Thusius NJ, Rummans TA, Gold MS. Medication-Assisted Treatment for Opioid-Use Disorder. Mayo Clin Proc. 2019 Oct; 94 (10):2072-2086 Epub 2019 Sept 19
    View PubMed
  17. Romanowicz M, Vande Voort JL, Shekunov J, Oesterle TS, Thusius NJ, Rummans TA, Croarkin PE, Karpyak VM, Lynch BA, Schak KM. The effects of parental opioid use on the parent-child relationship and children's developmental and behavioral outcomes: a systematic review of published reports. Child Adolesc Psychiatry Ment Health. 2019; 13:5 Epub 2019 Jan 12
    View PubMed
  18. Oesterle TS, Hitschfeld MJ, Lineberry TW, Schneekloth TD. CRAFFT as a Substance Use Screening Instrument for Adolescent Psychiatry Admissions. J Psychiatr Pract. 2015 Jul; 21 (4):259-66
    View PubMed
  19. Cockerill RG, Biggs BK, Oesterle TS, Croarkin PE. Antidepressant use and body mass index change in overweight adolescents: a historical cohort study. Innov Clin Neurosci. 2014 Nov-Dec; 11 (11-12):14-21
    View PubMed
  20. Rasmussen KG, Kung S, Lapid MI, Oesterle TS, Geske JR, Nuttall GA, Oliver WC, Abenstein JP. A randomized comparison of ketamine versus methohexital anesthesia in electroconvulsive therapy. Psychiatry Res. 2014 Feb 28; 215 (2):362-5 Epub 2013 Dec 21
    View PubMed
PST-20493239